Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

Kura Oncology (KURA) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of $0.15. This compares to a loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -600.00%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.51 per share when it actually produced a loss of $0.66, delivering a surprise of -29.41%.Over the last four quarters, the company h ...